Alder BioPharma Exec Litton Jumps to Alpine Immune Sciences

Mark Litton has been appointed president and chief operating officer of Alpine Immune Sciences (NASDAQ: [[ticker:ALPN]]). Litton comes to the Seattle drug developer from Bothell, WA-based Alder BioPharmaceuticals (NASDAQ: [[ticker:ALDR]]), where he had been chief business officer and treasurer since its founding in 2004. Jay Venkatesan, who was Alpine Immune Sciences’s president, will continue to serve as a director of the company and resume his role as a managing partner at Alpine BioVentures. Alpine Immune Sciences, led by former Dendreon CEO Mitch Gold, is developing protein-based immunotherapies to treat cancer and autoimmune disorders, among other diseases.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan